Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy

Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy

Kildey et al find that high levels of mitotic regulator CDCA3 correlates with sensitivity to platinum agents in non-small cell lung cancer patients and cell lines. They show that interfering with CDCA3 degradation through CK2 inhibition enhances CDCA3 levels and increases sensitivity to platinum age...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Katrina Kildey, Neha S. Gandhi, Katherine B. Sahin, Esha T. Shah, Eric Boittier, Pascal H. G. Duijf, Christopher Molloy, Joshua T. Burgess, Sam Beard, Emma Bolderson, Amila Suraweera, Derek J. Richard, Kenneth J. O’Byrne, Mark N. Adams
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/1fca8dd3265e4aecb2ae8d295b050bfa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Kildey et al find that high levels of mitotic regulator CDCA3 correlates with sensitivity to platinum agents in non-small cell lung cancer patients and cell lines. They show that interfering with CDCA3 degradation through CK2 inhibition enhances CDCA3 levels and increases sensitivity to platinum agents suggesting a therapeutic route.

Ejemplares similares